linjc16/ctgov huggingface dataset:
Relationship Between Endoplasmic Reticulum Stress and Pain in Patients With Endometriosis

Study Overview
=================
Brief Summary
-----------------
The correlation between painful symptoms (dysmenorrhea, dysparonia, dysuria, chronic pelvic pain) symptoms and endoplasmic reticulum stress was investigated in 86 patients diagnosed with endometriosis. For this, xbp-1 (x box binding protein-1) level was measured in patients. XBP-1 is an endoplasmic reticulum stress indicator and is known to be involved in pain pathogenesis.

Detailed Description
-----------------
Women between the ages of 18-50 who were diagnosed with endometriosis by surgery and ultrasound, without known rheumatological or metabolic diseases were included in the study. Most of the patients are composed of newly diagnosed patients.

Official Title
-----------------
Endoplasmic Reticulum Stress and Endometriosis Releated Pain

Conditions
-----------------
Endometriosis, Endoplasmic Reticulum Stress, Endometriosis-related Pain

Intervention / Treatment
-----------------
* Other: xbp-1 - endometriosis patients group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed endometriosis with ultrasound or surgery no metabolic diseases no rheumatological diseases Exclusion Criteria: Immune modulator, hormonal, anti-inflammatory use history in the last 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the correlations between the results of XBP-1 levels and the stages and pain symptoms of endometriosis. |  | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum XBP-1levels in patients wit endometriosis |  | 5 months |
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to prospectively assess whether there is any interval between first symptom and initial diagnosis that is experienced by patients with newly diagnosed alpha-1 antitrypsin deficiency (AATD) and then to assess whether this diagnostic interval is associated with worsened clinical status at the time of initial diagnosis.

Detailed Description
-----------------
The study protocol proposes to assess participants' clinical status based on the results of spirometry tests that are performed by the patient's managing physician as a routine part of clinical care of individuals with AATD within +/- 6 months of the initial diagnosis, subjects' St. George's Respiratory Questionnaire (SGRQ) at the time of initial diagnosis, and their COPD Assessment Test (CAT) result at the time of initial diagnosis of AATD (hereafter called time zero or T0 defined as the day on which the patient's test shows AATD from the blood work submitted for testing to Biocerna LLC by the patients' managing physicians as part of their routine clinical management). After offering verbal consent, subjects will complete a survey that assesses various clinical domains, including demographic features, how was AATD ascertained, initial symptom ascribable to AATD, the number of healthcare providers (and specific types of providers) seen before initial diagnosis, and clinical status at T0 or within a defined, relatively narrow temporal window (+/- 6 months) of T0. As in prior studies, the diagnostic interval will be defined as the duration between self-reported initial symptom of AATD (usually dyspnea in > 80% of cases3) and initial confirmed diagnosis of AATD (T0).

Official Title
-----------------
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: Assessing the Association Between Diagnostic Delay and Worsened Clinical Status

Conditions
-----------------
Alpha 1-Antitrypsin Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Positive AATD Test Result Exclusion Criteria: Previous Positive AATD Test Result Negative Test Result for AATD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults with an AAT Deficiency<br>Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recruitment | Track the number of subjects enrolled to determine if recruitment strategies need to be altered. | 3 months |
Added Value of N Acetyle Cysteine to Clomiphene Citrate in PCO

Study Overview
=================
Brief Summary
-----------------
PCO is one of the factors associated with delayed conception

Detailed Description
-----------------
In an attempt to induce ovulation Clomiphene citrate can be given in conjunction with N acetyle cysteine

Official Title
-----------------
The Added Value of n Acetyle Cysteine and Chromium to Clomiphene Citrate in PCO

Conditions
-----------------
PCO

Intervention / Treatment
-----------------
* Drug: Clomiphene plus metformin plus N acetyle cysteine in arm number 1
* Drug: Clomiphene citrate plus metformin with chromium
* Drug: clomiphene citrate plus metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with PCO Exclusion Criteria: women who donot have PCO

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Women who will receive clomiphe citrate plus N acetyle cysteine rally in arm number 1 And women who will receive clomiphene citrate and chromoum in arm number 22
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: clomiphene plus metformin plus N acetyle cysteine<br>Women who will receive clomiphene citrate plus metformin plus n acetyle cysteine | Drug: Clomiphene plus metformin plus N acetyle cysteine in arm number 1<br>* oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium<br>|
| Other: clomiphene plus metformin plus chromium<br>Women who will receive clomiphene plus metformin plus chromium | Drug: Clomiphene citrate plus metformin with chromium<br>* oral adminstration of clomiphene citrate plus metformin and chromium<br>|
| Other: clomiphen citrate plus metformin<br>Women who will receive clomiphene plus metformin | Drug: clomiphene citrate plus metformin<br>* oral adminstration of clomiphene citrate plus metformin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of women who will have mature follicles wih their size and number of mqture follicles The number of women who will have mature follicles | Assessment of women in both groups for size and number of follicles | within 2 weeks |
Clinical Outcome of Implant Removal Versus Retention After Posterior Fixation of Thoracolumbar Fractures

Study Overview
=================
Brief Summary
-----------------
Comparing clinical outcome between patients who underwent metal removal and those who retained the metal

Official Title
-----------------
Clinical Outcome of Implant Removal Versus Retention After Posterior Fixation of Thoracolumbar Spine Fractures

Conditions
-----------------
Thoracolumbar

Intervention / Treatment
-----------------
* Procedure: Metal removal


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-60 years Posterior fixation Six to nine months after fixation Neurologically free patient Fracture consolidation detected by ct Types A3&A4 fractures Exclusion Criteria: unstable fractures B&C pathological fractures multilevel fractures poly trauma patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Metal removal<br> | Procedure: Metal removal<br>* Implant removal after fracture consolidation after posterior fixation of thoracolumbar spine fractures<br>|
| No Intervention: Metal retention<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EQ-5D-5L questionnaire | Measuring the quality of life after metal removal | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oswestry disability index | Measuring the quality of life after metal removal or without removal | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metal removal
Brain Computer Interface Control of a Robotic Device

Study Overview
=================
Brief Summary
-----------------
Noninvasive Brain-Computer Interfaces (BCIs) have been used to control a number of virtual and physical objects through the voluntary modulation of brain rhythms. Current issues with noninvasive BCIs include exhausting motor imagery tasks and long training times required to achieve competent control. The investigators will address these issues within this protocol, examining new approaches to reduce the effort required by subjects to control a physical object in the task. The PI's hypothesis is: Control of a physical robotic device will increase the performance of subjects in BCI tasks that are analogous to virtual tasks due to greater engagement with a physical output.

Detailed Description
-----------------
Subjects will be recruited to participate in controlling a physical robotic device such as a quadcopter or a robotic arm using imagination of movement or other activities as detected by brain waves that can be used to control a robotic device. The subjects will be able to observe the controlling of a robotics device using one's thought and participate in multiple sessions to learn the skills to better control such a device.

Official Title
-----------------
Brain Computer Interface Control of a Robotic Device

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects for this study will be healthy, English speaking adult volunteers (18-64 years old). Exclusion Criteria: History of neurological deficit or traumatic brain injury.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Subjects<br>Noninvasive Brain Computer Interface Control | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of trials correct within each session of Brain Computer Interface experiments. | Accuracy and performance metrics of Brain-Computer Interface tasks over time. This will include the percent of trials correct, percent of trials completed, and time to completion within each session. Combining these metrics, we will examine subject learning over sessions with regression. Exact time frame of sessions will be determined by subject and equipment availability. | Session 1 through 10, within an average of 5 weeks. Each session separated by at least 24 hours. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Subjects
Transcranial Magnetic Stimulation (TMS) for Treatment of Auditory Hallucinations

Study Overview
=================
Brief Summary
-----------------
Transcranial magnetic stimulation (TMS) involves the use of magnetic fields to non-invasively stimulate the brain. Studies overseas have suggested this may be an effective and safe treatment for auditory hallucinations in patients with schizophrenia. This is a sham-controlled, double-blind trial of TMS stimulation for the treatment of auditory hallucinations in patients with schizophrenia.

Official Title
-----------------
A Pilot Study Using Transcranial Magnetic Stimulation (TMS) to Investigate the Role of the Temporal Cortex in Schizophrenic Patients With Auditory Hallucinations

Conditions
-----------------
Auditory Hallucinations

Intervention / Treatment
-----------------
* Device: Transcranial magnetic stimulation
* Device: Sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18, with DSM-IV diagnosis of Schizophrenia and auditory hallucinations of clear external origins, refractory to pharmacotherapy and occurring at least 5 times per day. Exclusion Criteria: Subjects with contraindications to TMS (e.g. epilepsy, pacemaker) or those with an unacceptably high risk (e.g. suicide risk) will be excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Stimulation will be given daily at a particular site for three days a week | Device: Transcranial magnetic stimulation<br>* Stimulation will be given daily at a particular site for three days a week<br>|
| Sham Comparator: 2<br> | Device: Sham<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daily Voices Ratings (Mental Health Research Institute, Victoria) |  | Daily | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Auditory hallucinations
To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.

Detailed Description
-----------------
Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF. Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN.

Official Title
-----------------
To Compare the Efficacy and Safety of TW vs Valsartan in the MN

Conditions
-----------------
Membranous Nephropathy

Intervention / Treatment
-----------------
* Drug: TW


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy-proven idiopathic membranous nephropathy Nephrotic syndrome with proteinuria (> 4 g/day) and serum albumin < 30 g/dl Age over 18 with informed consent Exclusion Criteria: Patient with abnormal liver function tests Prior therapy with sirolimus, CSA, MMF, tacrolimus or azathioprin, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days, Active/serious infection, Patient with hepatitis B surface antigen or who is hepatitis C antibody positive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: immunosuppressor<br>TW 120mg/d，Valsartan,160mg/d | Drug: TW<br>* TW,120mg/d<br>* Other names: TW,Tripterygium wilfordii Hook.f;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of membranous nephropathy |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate the safety and tolerability of TW vs ARB in treatment of MN |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TW, Valsartan, treatment, membranous nephropathy, proteinuria
COMPLICATIONS RELATED CARBOXYHEMOGLOBIN LEVELS IN SECOND HAND SMOKING PEDIATRIC TONSILLECTOMY PATIENTS

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to determine whether high carboxyhemoglobin level is a risk factor for postoperative adverse events in children exposured to carbon monoxide, especially enviromental tobacco smoke.

Detailed Description
-----------------
Also we want to measure bleeding volume and compare it with the carboxyhemoglobin levels.

Official Title
-----------------
COMPLICATIONS OF SECOND HAND SMOKING IN PEDIATRIC TONSILLECTOMY PATIENTS

Conditions
-----------------
Secondhand Smoking

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Patients 1-12 years old scheduled for adenotonsillectomy; written informed consent. Exclusion Criteria: Active smokers, history of prematurity, bleeding disorders, hemolysis, severe pulmonary disease, home oxygen use, and inpatient hospitalisation≥24 h.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlatin between carboxyhemoglobib levels of the second hand smoking children and postoperative complications and pain |  | Postoperative 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between carboxyhemoglobin levels of the second hand smoking children and intraoperative bleeding volume | Any relation between carboxyhemoglobin and bleeding? | Intraoperative period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Secondhand smoking, pain, postoperative complications
Effect of IDEA-070 on Pain and Inflammation Induced by PDT

Study Overview
=================
Brief Summary
-----------------
Primary objectives: effect of IDEA-070 compared to placebo on pain and inflammation induced by PDT. The primary objective is to detect a statistically significant difference of pain and inflammation induced by PDT in test areas treated with IDEA-070 compared to placebo-treated areas.

Official Title
-----------------
Safety and Efficacy of IDEA-070 for the Treatment of Pain and Inflammation Induced by Photodynamic Therapy of Actinic Keratosis

Conditions
-----------------
Actinic Keratosis

Intervention / Treatment
-----------------
* Drug: IDEA-070


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis ot actinic keratosis to be treated with PDT affecting equal sized areas of both sides of the head affecting at least 10% of the area of photoexposure Exclusion Criteria: Morpheaform basal cell carcinoma, Major hypertrophy of lesions, Porphyria, Topical treatment with 5-FU, cryotherapy, PDT, diclophenac sodium, and other less common treatments on the treatment area or systemic treatment within 3 month prior to screening, Concomitant use of other analgesics including topical NSAIDs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: IDEA-070|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |